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Commentary Platelet Crossmatching
In current practice, platelet transfusion begins with randomly selected platelets, either whole blood derived platelet concentrates or platelet prepared by apheresis. This approach continues until the patient is refractory. Most immunogenic refractoriness results from antibodies to human leukocyte antigen (HLA). It is important to emphasize that clinical refractoriness is often due not to alloimmunization but, rather, to clinical factors such as infection, splenomegaly, or disseminated intravascular coagulation. This, it would make sense to perform one or more serologic tests to prove that alloimmunization was present before taking any decision to platelet transfusion. In such condition, HLA-matched platelet (once HLA phenotype in known); crossmatched platelets or HLA antigen negative platelet are the choices for better response and controlled hemostasis. In general, platelets are required immediately or very soon and the method employed is based upon the availability. Crossmatched platelet may be obtained more quickly than HLA-matched platelets. In addition crossmatched platelets can be used both for diagnosis and treatment, as antibody detection is inherent to its testing process. Crossmatched products have been shown to have a longer survival post-transfusion than un-crossmatched platelets. Another benefit of cross-matching as compared to HLA-matched platelet is the potential larger pool of compatible donor.
With the advancement of technology for the management of platelet alloimmunization, crossmatching is an excellent way to begin support in a patient needing product urgently. It 
